SECORIM® ABO
Fighting the world’s organ shortage
SECORIM®-ABO enables transplantations across blood group barriers by specific removal of the organ recipient’s blood group anti-A and/or anti-B antibodies (ABO-antibodies).
Fighting the world’s organ shortage
SECORIM®-ABO has its potential in living-donor kidney transplantation with further use for other transplantations, such as liver, heart, lung, bone marrow and stem cells. Clinical results and data of transplantations performed after specific removal of incompatible ABO-antibodies by immunoadsorption in combination with immunosuppression report successful clinical outcomes similar to those of ABO compatible kidney transplantation, both short and long-term.
Selective immunoadsorption treatment, potentially increases the number of transplantations from living donors.